Scientists at Northwestern University have developed the largest open-access resource of its kind to help researchers shave ...

SCD is the most common lethal monogenic disease globally, arising from a mutation in the hemoglobin beta-globin (HBB) gene that results in hemoglobin S, which can cause red blood cell sickling ...

The promise of genome editing to help understand human diseases and create new therapies is vast, but technological ...

Type 2 diabetes mellitus (T2DM) is a highly prevalent metabolic disorder worldwide. Beyond glucose dysregulation, it exerts ...

Sickle cell disease (SCD) is a genetic disorder of the red blood cells caused by a mutation in the HBB gene. This gene encodes a protein that is a key component of hemoglobin, a protein complex ...

Bankrupt genetic-testing firm 23andMe agreed to sell its data bank, which once contained DNA samples from about 15 million people, to the drug developer Regeneron Pharmaceuticals for $256 million.

They would use a technology known as CRISPR, a personalized gene-editing therapy, to find the one uniquely mutated gene out of 20,000 in his little body, and fix it. KJ subsequently received three ...

Tessera Therapeutics Presented new preclinical data in non-human primates (NHP) for alpha-1 antitrypsin deficiency (AATD) and phenylketonuria (PKU), where RNA Gene Writer achieved an estimated 76% ...

In this editorial, the authors describe the foundations of an N-of-1 gene-editing study to treat an infant with a urea-cycle disorder. 2 Department of Chemistry and Biochemistry, University of ...

Hamilton Beach Brands Holding Company, together with its subsidiaries, designs, markets, and distributes small electric household and specialty housewares appliances in the United States and ...

Instead, KJ has made medical history. The baby, now 9 ½ months old, became the first patient of any age to have a custom gene-editing treatment, according to his doctors. He received an infusion ...

Get Instant Summarized Text (Gist) A child with severe carbamoyl phosphate synthetase 1 (CPS1) deficiency received a personalized CRISPR-based gene editing therapy, resulting in improved metabolic ...